entertainment -WSS

entertainment

author：fashion 2025-09-29 22:49:49 - browse：22

Scientist walks up a strand of DNA -- First Opinion coverage from STAT — Adobe

Eli Lilly said Tuesday that it will pay $200 million to gene-editing firm Beam Therapeutics for Beam’s stake in Verve Therapeutics, another gene-editing company focused on treatments for heart disease.

The deal, which also includes future milestone payments, is evidence that despite the pressure on biotechnology stocks there is still interest in very early cutting-edge technologies among big pharmaceutical players. It also provides Beam, which announced on Oct. 19 that it would cut 100 jobs, or 20% of its workforce, to save cash, a large infusion of money.

“This is like a true win-win-win deal, which is rare in this business, but it’s really, really exciting to see,” said John Evans, Beam’s CEO, in an interview with STAT.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： Senators: Long

hotspot

WSS

Why are Kaiser Permanente staff considering a strike?

CDC advisers recommend seasonal use of Pfizer RSV shot

Medicare threatens to cut off funding for HCA's Mission hospital

Why did Pfizer dish out millions for a Super Bowl ad?

FDA panel to weigh approval of NurOwn, controversial ALS drug

For Medicare Advantage, Democrats want stronger protections around AI

entertainment

entertainment

focus

At least 13 dead in Texas as scorching temps continue

Thermo Fisher plant for manufacturing gene therapies to expand

At least 13 dead in Texas as scorching temps continue

KalVista pill reduced swelling 'attacks' caused by genetic disease

Wildfire smoke exposes gaps in outdoor worker protections

Readout Newsletter: Biogen, Rocket Pharma, KalVista, and more

Malaria cases in Florida and Texas: Here’s what you need to know

CommonSpirit Health keeps growing, even as it loses money

ChatGPT in medicine: STAT answers readers' burning questions

Emergency workers more likely to restrain Black patients: study

focus

Senate HELP committee spars over health care workforce policies

For Medicare Advantage, Democrats want stronger protections around AI

Readout Newsletter: Biogen, Rocket Pharma, KalVista, and more

To avoid data mishandling cases, universities eye AI and other tools

Case for ALS therapy Nurown relies on ‘deficient’ data, FDA finds

Robert F. Kennedy is pitching centrism on health, even on abortion

hotspot

hotspot

focus

hotspot